Neurogene
NGNE
31 hedge funds and large institutions have $14.4M invested in Neurogene in 2023 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 10 closing their positions.
8.34% more ownership
Funds ownership: 2.02% → 10.36% (+8.3%)
1% more capital invested
Capital invested by funds: $14.3M → $14.4M (+$72.2K)
14% less funds holding
Funds holding: 36 → 31 (-5)
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$1.69M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.14M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.11M |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$347K |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$92K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$2.57M |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$715K |
| 3 |
Millennium Management
New York
|
-$311K |
| 4 |
Morgan Stanley
New York
|
-$209K |
| 5 |
PFMU
Privium Fund Management (UK)
London,
United Kingdom
|
-$94.9K |
NGNE Hedge Fund Activity: Q3 2023 in Review
31 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q3 2023, worth a combined $14.4M — up 0.5% from $14.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of NGNE and 5 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 8 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $1.69M. The largest seller was Lynx1 Capital Management, exiting entirely with an estimated $2.57M sold.
- 31 institutional investors held Neurogene (NGNE) as of Q3 2023, down from 36 in Q2 2023.
- Funds reported $14.4M of Neurogene stock for Q3 2023, up 0.5% quarter-over-quarter.
- 5 funds opened new Neurogene positions in Q3 2023 and 10 closed out, a net change of -5 holders.
- The largest Neurogene buyer in Q3 2023 was Baker Bros. Advisors, an estimated $1.69M added.
- The largest Neurogene seller in Q3 2023 was Lynx1 Capital Management, an estimated $2.57M sold.
Based on aggregated 13F filings for Q3 2023.